MediPharm Labs (LABS) Q2 2024 earnings summary

Executive summary

• Achieved near breakeven Adjusted EBITDA in Q2 2024, with a loss of CAD 0.1 million (USD 124K), marking a 96% year-over-year improvement and the best result in over three years.

• Revenue reached CAD 10.3 million (USD 10.3M), the highest in over three years, up 8% year-over-year and 6% sequentially, with international sales comprising 44%.

• Gross profit margin rose to 33% (37% adjusted), the highest in over four years, driven by cost reductions and favorable product mix.

• Significant restructuring, including facility sales, integration of VIVO and Canna Farms, and operational streamlining, reduced costs and improved service.

• Strong cash position of CAD 16 million and less than CAD 3 million in debt, with additional cash expected from asset sales.

Financial highlights

• Adjusted EBITDA loss improved 96% year-over-year and 87% sequentially, reaching CAD 0.1 million (USD 124K).

• Gross profit was CAD 3.4 million (33% margin), the highest in over four years; adjusted gross profit was 37%.

• General and administrative expenses dropped to CAD 3.9 million, down from CAD 5.8 million year-over-year.

• Total operating expenses were CAD 5.4 million, down CAD 2.1 million from prior year.

• Cash burn in Q2 was approximately CAD 1 million.

Outlook and guidance

• Management expects continued progress toward profitability and positive cash flow in the second half of 2024, targeting positive cash flow in 2025.

• Continued focus on international expansion, especially in Europe, Australia, and Brazil.

• Anticipates revenue from a pharmaceutical partner in Brazil starting Q4 2024.

• Ongoing evaluation of M&A opportunities, with a focus on accretive deals and synergy in Canada and internationally.

• Anticipated annual cost savings of CAD 1 million from operational streamlining and potential additional cash from the sale of the Hope Facility.